Novel in vitro Disease-relevant Assay System

Request Number REQ4368440
Due Date March 14, 2018
Request for Proposal Details
RFP Title
Novel in vitro Disease-relevant Assay System
RFP Description

NineSigma, representing Astellas Pharma Inc. (, seeks a novel in vitro Disease-relevant assay system (e.g. phenotype assay etc.). Astellas aims at developing the proposed assay system into high-throughput screening system and using for screening of their compound library. They are eager to collaborate with potential partners willing to work on this project.


The client has been engaged in the R&D of new drugs to address unmet medical needs. As a part of this challenge, they actively conducts R&D not only for developing new compounds, but also for exploring new indications of marketed drugs or in-house compounds for which R&D was discontinued. In these efforts, to improve the efficiency of drug discovery and launch drugs earlier, it is crucial to establish an in vitro assay system with high extrapolation that reflects a Disease-relevant condition in humans. Furthermore, high-throughput technology is required for efficient drug discovery. They aims at achieving this point combining promising assay system possessed partners with Astellas’s proprietary advanced platform technologies


Therefore, the client has issued this open request to seek a wide range of potential organizations that have already developed highly unique in vitro assay system.




Key Success Criteria

Requirements of the in vitro assay system

The client seeks an in vitro assay system that fulfills the following requirements:

  • Should have high correlation with a disease with unmet medical needs and high uniqueness.
    • Should be able to clearly specify anticipated target diseases and their rationale.
    • Proposals that meet the client’s needs and do not conflict with internal projects are given higher priority.


Anticipated Project Phases or Project Plan

Respondents should submit proposals using the attached Response Template.


Proposals will be evaluated primarily and then successful providers can obtain the opportunity of direct discussion with the client. The client may execute non-disclosure agreements (NDA) with selected respondents and seek further information disclosure to select the best candidates. If the client discovers a potential proposal, they will conclude a technical guidance agreement with the potential partner, and if necessary, a license agreement. (If effective compounds are found as a result of screening at Astellas, the client may conclude a joint research agreement with the potential partner, separately.)




Preferred Collaboration types
  • Joint Development
  • Contract Research
  • Technology Licensing
Items to be submitted

Responses will use the Proposal Template which is linked to the “attachments” shown at the bottom this page and include the following items:


  • Overview of the proposed in vitro assay system (characteristics, novelty, correlation with human diseases, etc.)
  • Target diseases
  • Rationale and data supporting the appropriateness of the use in drug discovery for the above diseases
  • Presence/absence of higher assay system (e.g. assay system using in vivo system and patients’ tissue) (Respondents with this system should describe the overview; respondents without this system can describe the plan only.)
  • Request regarding the condition of collaboration and the necessary budget
  • Current status of the intellectual property related to the proposed technology
  • Research achievements



Area of Interest
Request Priority